Amgen 2013 Annual Report Download - page 9


We maintain sales and marketing forces primarily in the United States and Europe. Additionally, we continue to expand the commercialization and
marketing of our products into new geographic markets, including such countries as Japan and China. This is achieved either through building our own sales
and marketing force or in partnership with third parties. See Business Relationships. Together with our partners, we market our products to healthcare
providers, including physicians or their clinics, dialysis centers, hospitals and pharmacies. We also market certain products directly to consumers through
direct-to-consumer print and television advertising, as well as through the Internet. See Government Regulation — Regulation of Product Marketing and
Promotion for a discussion of government regulation of product marketing and promotion.
In the United States, we sell primarily to pharmaceutical wholesale distributors. We utilize those wholesale distributors as the principal means of
distributing our products to U.S. healthcare providers. In Europe, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors
depending on the distribution practice in each country. We monitor the financial condition of our larger customers, and we limit our credit exposure by setting
credit limits and, for certain customers, may require letters of credit.
Our product sales to three large wholesalers, AmerisourceBergen Corporation, McKesson Corporation and Cardinal Health, Inc., each accounted for
more than 10% of total revenues for each of the years ended December 31, 2013, 2012 and 2011. On a combined basis, these wholesalers accounted for
approximately 93%, 94% and 90% of our gross product sales in the United States, respectively, and approximately 75%, 76% and 72% of our total
worldwide gross revenues, respectively.
For financial information related to our one business segment, see Part IV — Consolidated Statements of Income, Consolidated Balance Sheets and
Note 19, Segment information, to the Consolidated Financial Statements.
We market our principal products primarily in the United States in cancer care, inflammation, nephrology and bone disease. The following charts
show our product sales by principal product and by geography for each of the years ended December 31, 2013, 2012 and 2011.
Neulasta® (pegfilgrastim)/NEUPOGEN®(filgrastim)
We market Neulasta®, a pegylated protein based on the filgrastim molecule, and NEUPOGEN ®, a recombinant-methionyl human granulocyte colony-
stimulating factor (G-CSF), primarily in the United States and Europe. Neulasta ® was launched in 2002 and is indicated to decrease the incidence of infection
associated with chemotherapy-induced febrile neutropenia in cancer patients with non-myeloid malignancies. NEUPOGEN ® was launched in 1991 and is
approved for five different indications. It is used primarily for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-
myeloid malignancies undergoing myelosuppressive chemotherapy associated with a significant incidence of severe neutropenia with fever.
3